TWI753168B - 用於血友病ｂ基因療法之編碼具有增強表現的重組ｆｉｘ變異體之病毒載體 - Google Patents
用於血友病ｂ基因療法之編碼具有增強表現的重組ｆｉｘ變異體之病毒載體 Download PDFInfo
- Publication number
- TWI753168B TWI753168B TW107117388A TW107117388A TWI753168B TW I753168 B TWI753168 B TW I753168B TW 107117388 A TW107117388 A TW 107117388A TW 107117388 A TW107117388 A TW 107117388A TW I753168 B TWI753168 B TW I753168B
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- factor
- sequence
- polynucleotide
- nucleic acid
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title claims abstract description 40
- 230000014509 gene expression Effects 0.000 title abstract description 36
- 230000001965 increasing effect Effects 0.000 title description 33
- 208000009292 Hemophilia A Diseases 0.000 title description 14
- 208000031220 Hemophilia Diseases 0.000 title description 9
- 239000013603 viral vector Substances 0.000 title description 8
- 102100022641 Coagulation factor IX Human genes 0.000 claims abstract description 947
- 108010076282 Factor IX Proteins 0.000 claims abstract description 929
- 229960004222 factor ix Drugs 0.000 claims abstract description 902
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 711
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 711
- 239000002157 polynucleotide Substances 0.000 claims abstract description 711
- 239000013598 vector Substances 0.000 claims abstract description 36
- 208000009429 hemophilia B Diseases 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 508
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 480
- 229920001184 polypeptide Polymers 0.000 claims description 479
- 150000007523 nucleic acids Chemical class 0.000 claims description 231
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 164
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 94
- 102000039446 nucleic acids Human genes 0.000 claims description 90
- 108020004707 nucleic acids Proteins 0.000 claims description 90
- 125000003729 nucleotide group Chemical group 0.000 claims description 81
- 239000002773 nucleotide Substances 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 72
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 67
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 66
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 46
- 238000006467 substitution reaction Methods 0.000 claims description 35
- 210000004185 liver Anatomy 0.000 claims description 18
- 241000702421 Dependoparvovirus Species 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000010076 replication Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000014621 translational initiation Effects 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 abstract description 4
- 108020004705 Codon Proteins 0.000 description 365
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 122
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 90
- 108091026890 Coding region Proteins 0.000 description 76
- 230000000694 effects Effects 0.000 description 72
- 150000001413 amino acids Chemical class 0.000 description 58
- 108010028825 factor IX Cambridge Proteins 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 35
- 230000003213 activating effect Effects 0.000 description 28
- 238000003776 cleavage reaction Methods 0.000 description 26
- 230000007017 scission Effects 0.000 description 26
- 239000002243 precursor Substances 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 22
- 230000001105 regulatory effect Effects 0.000 description 22
- 102200063714 rs137852283 Human genes 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- 108010048049 Factor IXa Proteins 0.000 description 17
- 108010054218 Factor VIII Proteins 0.000 description 16
- 125000003277 amino group Chemical group 0.000 description 16
- 229960000027 human factor ix Drugs 0.000 description 16
- 230000001976 improved effect Effects 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 102000001690 Factor VIII Human genes 0.000 description 15
- 241000700605 Viruses Species 0.000 description 15
- 229960000301 factor viii Drugs 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- 238000011282 treatment Methods 0.000 description 14
- 210000002845 virion Anatomy 0.000 description 13
- 108091029430 CpG site Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000009256 replacement therapy Methods 0.000 description 10
- 230000035772 mutation Effects 0.000 description 9
- 230000009261 transgenic effect Effects 0.000 description 9
- 239000013607 AAV vector Substances 0.000 description 8
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 8
- 108010022999 Serine Proteases Proteins 0.000 description 8
- 102000012479 Serine Proteases Human genes 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000035602 clotting Effects 0.000 description 8
- 102100026735 Coagulation factor VIII Human genes 0.000 description 7
- 108010074864 Factor XI Proteins 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 208000034158 bleeding Diseases 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 206010053567 Coagulopathies Diseases 0.000 description 6
- 108010014173 Factor X Proteins 0.000 description 6
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 206010016077 Factor IX deficiency Diseases 0.000 description 5
- 201000003542 Factor VIII deficiency Diseases 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 4
- 102220569711 Coagulation factor IX_K311T_mutation Human genes 0.000 description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 4
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 208000011664 congenital factor XI deficiency Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 201000007219 factor XI deficiency Diseases 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 108091029523 CpG island Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 238000007820 coagulation assay Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091005508 Acid proteases Proteins 0.000 description 2
- 101800001401 Activation peptide Proteins 0.000 description 2
- 102400000069 Activation peptide Human genes 0.000 description 2
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 101150044789 Cap gene Proteins 0.000 description 2
- 102220569710 Coagulation factor IX_Y305F_mutation Human genes 0.000 description 2
- 102220569709 Coagulation factor IX_Y391T_mutation Human genes 0.000 description 2
- 108010080805 Factor XIa Proteins 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 2
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 101100172173 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) hcr-1 gene Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 208000026578 Severe hemophilia B Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 102220032401 rs104895236 Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102220522914 Ataxin-7-like protein 3B_I316F_mutation Human genes 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 102220569334 Carbohydrate-responsive element-binding protein_Q241H_mutation Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 102220584181 Coagulation factor IX_A366D_mutation Human genes 0.000 description 1
- 102220583800 Coagulation factor IX_C178W_mutation Human genes 0.000 description 1
- 102220627539 Coagulation factor IX_C28Y_mutation Human genes 0.000 description 1
- 102220583696 Coagulation factor IX_C396F_mutation Human genes 0.000 description 1
- 102220627890 Coagulation factor IX_C97S_mutation Human genes 0.000 description 1
- 102220628214 Coagulation factor IX_E53A_mutation Human genes 0.000 description 1
- 102220628217 Coagulation factor IX_E54D_mutation Human genes 0.000 description 1
- 102220628216 Coagulation factor IX_E54G_mutation Human genes 0.000 description 1
- 102220628245 Coagulation factor IX_E66V_mutation Human genes 0.000 description 1
- 102220628239 Coagulation factor IX_E67K_mutation Human genes 0.000 description 1
- 102220628241 Coagulation factor IX_E73K_mutation Human genes 0.000 description 1
- 102220570248 Coagulation factor IX_F424V_mutation Human genes 0.000 description 1
- 102220628218 Coagulation factor IX_F55C_mutation Human genes 0.000 description 1
- 102220628238 Coagulation factor IX_F71S_mutation Human genes 0.000 description 1
- 102220583859 Coagulation factor IX_G253E_mutation Human genes 0.000 description 1
- 102220584185 Coagulation factor IX_G363W_mutation Human genes 0.000 description 1
- 102220628220 Coagulation factor IX_G58A_mutation Human genes 0.000 description 1
- 102220628243 Coagulation factor IX_G58E_mutation Human genes 0.000 description 1
- 102220628246 Coagulation factor IX_G58R_mutation Human genes 0.000 description 1
- 102220627535 Coagulation factor IX_I17N_mutation Human genes 0.000 description 1
- 102220584130 Coagulation factor IX_I344L_mutation Human genes 0.000 description 1
- 102220583733 Coagulation factor IX_I390F_mutation Human genes 0.000 description 1
- 102220627590 Coagulation factor IX_K45N_mutation Human genes 0.000 description 1
- 102220627589 Coagulation factor IX_L20S_mutation Human genes 0.000 description 1
- 102220584243 Coagulation factor IX_L321Q_mutation Human genes 0.000 description 1
- 102220583731 Coagulation factor IX_L383I_mutation Human genes 0.000 description 1
- 102220628215 Coagulation factor IX_L52S_mutation Human genes 0.000 description 1
- 102220583746 Coagulation factor IX_M394K_mutation Human genes 0.000 description 1
- 102220584238 Coagulation factor IX_N328K_mutation Human genes 0.000 description 1
- 102220584237 Coagulation factor IX_N328Y_mutation Human genes 0.000 description 1
- 102220628221 Coagulation factor IX_N48I_mutation Human genes 0.000 description 1
- 102220584240 Coagulation factor IX_P333H_mutation Human genes 0.000 description 1
- 102220584234 Coagulation factor IX_P333T_mutation Human genes 0.000 description 1
- 102220627585 Coagulation factor IX_R43L_mutation Human genes 0.000 description 1
- 102220627588 Coagulation factor IX_R43Q_mutation Human genes 0.000 description 1
- 102220627587 Coagulation factor IX_R43W_mutation Human genes 0.000 description 1
- 102220628219 Coagulation factor IX_R46S_mutation Human genes 0.000 description 1
- 102220628222 Coagulation factor IX_R46T_mutation Human genes 0.000 description 1
- 102220570246 Coagulation factor IX_S430T_mutation Human genes 0.000 description 1
- 102220628234 Coagulation factor IX_S49P_mutation Human genes 0.000 description 1
- 102220584168 Coagulation factor IX_T342K_mutation Human genes 0.000 description 1
- 102220627884 Coagulation factor IX_T84R_mutation Human genes 0.000 description 1
- 102220570326 Coagulation factor IX_V227D_mutation Human genes 0.000 description 1
- 102220627584 Coagulation factor IX_V30I_mutation Human genes 0.000 description 1
- 102220584167 Coagulation factor IX_W356C_mutation Human genes 0.000 description 1
- 102220570247 Coagulation factor IX_W431G_mutation Human genes 0.000 description 1
- 102220627887 Coagulation factor IX_Y91C_mutation Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 229940117942 Factor IX inhibitor Drugs 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000823435 Homo sapiens Coagulation factor IX Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 102220475908 Peroxisome assembly protein 12_W431R_mutation Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 102220517173 Polyserase-2_F395Y_mutation Human genes 0.000 description 1
- 102220531949 Postacrosomal sheath WW domain-binding protein_C170F_mutation Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102220574648 Protein Churchill_N283G_mutation Human genes 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102220492896 Protein phosphatase 1 regulatory subunit 7_E433Q_mutation Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 102000044437 S1 domains Human genes 0.000 description 1
- 108700036684 S1 domains Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 101150069374 Serpina1 gene Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940004970 bebulin Drugs 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102220401920 c.1349A>G Human genes 0.000 description 1
- 102200046724 c.416G>A Human genes 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 229940052349 human coagulation factor ix Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- 108010030972 nonacog beta pegol Proteins 0.000 description 1
- 229950003692 nonacog beta pegol Drugs 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102220319212 rs1040336692 Human genes 0.000 description 1
- 102220032482 rs104895501 Human genes 0.000 description 1
- 102220214534 rs1060502025 Human genes 0.000 description 1
- 102220218274 rs1060503460 Human genes 0.000 description 1
- 102200012179 rs111033841 Human genes 0.000 description 1
- 102220235613 rs1131691931 Human genes 0.000 description 1
- 102220040064 rs116474782 Human genes 0.000 description 1
- 102200149813 rs121434303 Human genes 0.000 description 1
- 102200133198 rs121913084 Human genes 0.000 description 1
- 102200064132 rs137852226 Human genes 0.000 description 1
- 102200064131 rs137852228 Human genes 0.000 description 1
- 102200064130 rs137852229 Human genes 0.000 description 1
- 102200064135 rs137852230 Human genes 0.000 description 1
- 102200064134 rs137852231 Human genes 0.000 description 1
- 102200064077 rs137852233 Human genes 0.000 description 1
- 102200063899 rs137852237 Human genes 0.000 description 1
- 102200063905 rs137852238 Human genes 0.000 description 1
- 102200063908 rs137852240 Human genes 0.000 description 1
- 102200063909 rs137852241 Human genes 0.000 description 1
- 102200063912 rs137852243 Human genes 0.000 description 1
- 102200063913 rs137852243 Human genes 0.000 description 1
- 102200063918 rs137852246 Human genes 0.000 description 1
- 102200063917 rs137852247 Human genes 0.000 description 1
- 102200063801 rs137852249 Human genes 0.000 description 1
- 102200063806 rs137852251 Human genes 0.000 description 1
- 102200063692 rs137852254 Human genes 0.000 description 1
- 102200063697 rs137852257 Human genes 0.000 description 1
- 102200063710 rs137852259 Human genes 0.000 description 1
- 102200063680 rs137852265 Human genes 0.000 description 1
- 102200063743 rs137852266 Human genes 0.000 description 1
- 102200063746 rs137852268 Human genes 0.000 description 1
- 102200063748 rs137852269 Human genes 0.000 description 1
- 102200063657 rs137852273 Human genes 0.000 description 1
- 102200064073 rs137852274 Human genes 0.000 description 1
- 102200063698 rs137852275 Human genes 0.000 description 1
- 102200063672 rs137852276 Human genes 0.000 description 1
- 102200063660 rs137852277 Human genes 0.000 description 1
- 102200063661 rs137852278 Human genes 0.000 description 1
- 102200063678 rs137852280 Human genes 0.000 description 1
- 102200063655 rs137852281 Human genes 0.000 description 1
- 102200035378 rs137853119 Human genes 0.000 description 1
- 102220036887 rs141690729 Human genes 0.000 description 1
- 102220211061 rs144431930 Human genes 0.000 description 1
- 102220217079 rs144996870 Human genes 0.000 description 1
- 102200080180 rs146093755 Human genes 0.000 description 1
- 102200113001 rs1554292759 Human genes 0.000 description 1
- 102220242010 rs1556049714 Human genes 0.000 description 1
- 102200108795 rs199473095 Human genes 0.000 description 1
- 102220024959 rs199473657 Human genes 0.000 description 1
- 102220151651 rs201069745 Human genes 0.000 description 1
- 102220058136 rs201313861 Human genes 0.000 description 1
- 102220065585 rs201550119 Human genes 0.000 description 1
- 102200063915 rs267606792 Human genes 0.000 description 1
- 102200062090 rs267606998 Human genes 0.000 description 1
- 102200071359 rs28934605 Human genes 0.000 description 1
- 102220117809 rs371679886 Human genes 0.000 description 1
- 102220081262 rs374020067 Human genes 0.000 description 1
- 102200151009 rs375824494 Human genes 0.000 description 1
- 102200063975 rs387906481 Human genes 0.000 description 1
- 102220005645 rs387906545 Human genes 0.000 description 1
- 102220121339 rs553367989 Human genes 0.000 description 1
- 102220007768 rs587777835 Human genes 0.000 description 1
- 102220036485 rs587779843 Human genes 0.000 description 1
- 102220140277 rs61733577 Human genes 0.000 description 1
- 102200047029 rs61752153 Human genes 0.000 description 1
- 102200059854 rs61754369 Human genes 0.000 description 1
- 102200028587 rs61754453 Human genes 0.000 description 1
- 102200058123 rs63750450 Human genes 0.000 description 1
- 102220032160 rs67993095 Human genes 0.000 description 1
- 102220062460 rs730881681 Human genes 0.000 description 1
- 102220330466 rs746408860 Human genes 0.000 description 1
- 102220196629 rs747237113 Human genes 0.000 description 1
- 102220278848 rs749272832 Human genes 0.000 description 1
- 102220177345 rs758862580 Human genes 0.000 description 1
- 102220126350 rs764155637 Human genes 0.000 description 1
- 102220147544 rs774976776 Human genes 0.000 description 1
- 102220152012 rs777614964 Human genes 0.000 description 1
- 102220069574 rs794727703 Human genes 0.000 description 1
- 102220071215 rs794728045 Human genes 0.000 description 1
- 102220105426 rs879254514 Human genes 0.000 description 1
- 102220105455 rs879254536 Human genes 0.000 description 1
- 102220171381 rs886052584 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 102220504537 von Hippel-Lindau disease tumor suppressor_G106D_mutation Human genes 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509616P | 2017-05-22 | 2017-05-22 | |
| US62/509,616 | 2017-05-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201900184A TW201900184A (zh) | 2019-01-01 |
| TWI753168B true TWI753168B (zh) | 2022-01-21 |
Family
ID=62621009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107117388A TWI753168B (zh) | 2017-05-22 | 2018-05-22 | 用於血友病ｂ基因療法之編碼具有增強表現的重組ｆｉｘ變異體之病毒載體 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10842853B2 (https=) |
| EP (1) | EP3630974A1 (https=) |
| JP (1) | JP6961171B2 (https=) |
| KR (2) | KR102386890B1 (https=) |
| CN (2) | CN110945127B (https=) |
| AR (1) | AR112057A1 (https=) |
| AU (1) | AU2018272831B2 (https=) |
| BR (1) | BR112019024256A2 (https=) |
| CA (1) | CA3064730A1 (https=) |
| CL (2) | CL2019003395A1 (https=) |
| CO (1) | CO2019012885A2 (https=) |
| IL (2) | IL280637B2 (https=) |
| MX (2) | MX2019013836A (https=) |
| NZ (1) | NZ759034A (https=) |
| TW (1) | TWI753168B (https=) |
| WO (1) | WO2018217731A1 (https=) |
| ZA (1) | ZA201907716B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| AU2019360270B2 (en) | 2018-10-18 | 2025-08-07 | Intellia Therapeutics, Inc. | Compositions and methods for expressing factor IX. |
| TWI851647B (zh) * | 2019-01-16 | 2024-08-11 | 日商武田藥品工業股份有限公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 |
| US11596671B2 (en) * | 2019-02-01 | 2023-03-07 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression |
| AU2020242945B2 (en) * | 2019-03-19 | 2025-06-26 | CSL Innovation Pty Ltd | Factor IX variants and uses thereof in therapy |
| CN114207135A (zh) * | 2019-06-11 | 2022-03-18 | 夏尔人类遗传性治疗公司 | 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送 |
| CN114375205A (zh) | 2019-06-20 | 2022-04-19 | 武田药品工业株式会社 | 用基于病毒的基因疗法进行治疗的方法 |
| CN110684798A (zh) * | 2019-09-03 | 2020-01-14 | 深圳新诺微环生物科技有限公司 | 肌肉靶向的微环dna基因治疗 |
| EP4087489B1 (en) * | 2020-01-08 | 2025-05-14 | Vitruvia Holdings Inc. | Methods and computing system for processing ultrasound image to determine health of subdermal tissue |
| JP2023510392A (ja) * | 2020-01-16 | 2023-03-13 | 武田薬品工業株式会社 | フェニルケトン尿症に対するアデノ随伴ウイルスベースの遺伝子治療 |
| TW202246505A (zh) * | 2021-03-05 | 2022-12-01 | 俄羅斯聯邦商亞那拜恩有限公司 | 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途 |
| JP2024521537A (ja) * | 2021-06-23 | 2024-05-31 | フロンテーラ セラピューティクス，インク． | 血友病ｂを処置するための組成物および方法 |
| CN114277057B (zh) * | 2021-07-09 | 2023-10-13 | 上海天泽云泰生物医药有限公司 | 用于治疗或预防b型血友病的重组腺相关病毒载体和方法 |
| US20230149563A1 (en) * | 2021-10-27 | 2023-05-18 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for expressing factor ix for hemophilia b therapy |
| CN118460618A (zh) * | 2022-04-19 | 2024-08-09 | 康霖生物科技（杭州）有限公司 | 一种用于遗传性凝血因子缺乏病治疗的核酸构建体 |
| WO2025143742A1 (ko) * | 2023-12-26 | 2025-07-03 | 삼성바이오에피스 주식회사 | 혈액응고인자 IX를 암호화하는 코돈-최적화된 폴리뉴클레오티드 및 이를 포함하는 rAAV 생산용 플라스미드 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2438931B1 (en) * | 2004-09-22 | 2013-11-13 | St. Jude Children's Research Hospital | Improved expression of factor IX in gene therapy vectors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
| EP0710288B1 (en) | 1993-06-10 | 2006-04-05 | Genetic Therapy, Inc. | Adenoviral vectors for treatment of hemophilia |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| JPH10506530A (ja) | 1994-09-23 | 1998-06-30 | ザ ジェネラル ホスピタル コーポレーション | 哺乳類細胞において外来遺伝子を発現する非哺乳類ｄｎａウイルスの使用 |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5858351A (en) | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
| US5866552A (en) | 1996-09-06 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Method for expressing a gene in the absence of an immune response |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| EP1005376B1 (en) | 1997-03-14 | 2010-11-03 | The Children's Hospital of Philadelphia | Compositions for use in gene therapy for treatment of hemophilia |
| US6531298B2 (en) | 1997-07-21 | 2003-03-11 | The University Of North Carolina At Chapel Hill | Factor IX antihemophilic factor with increased clotting activity |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6924365B1 (en) | 1998-09-29 | 2005-08-02 | Transkaryotic Therapies, Inc. | Optimized messenger RNA |
| WO2000074688A1 (en) | 1999-06-08 | 2000-12-14 | The Children's Hospital Of Philadelphia | Methods for preventing formation of inhibitory antibodies in the setting of gene therapy |
| CN1148228C (zh) | 2000-08-30 | 2004-05-05 | 夏家辉 | 治疗血友病b的基因药物及其制备方法 |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| EP2423307A1 (en) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IV polypeptides and use thereof for treatment |
| CA2722238C (en) | 2008-04-22 | 2017-11-28 | Life Sciences Research Partners Vzw | Liver-specific nucleic acid regulatory elements and methods and use thereof |
| TR201813067T4 (tr) | 2008-09-15 | 2018-09-21 | Uniqure Biopharma B V | Faktör IX polipeptit mutantı, bunun kullanımları ve bunu üretmeye yönelik bir yöntem. |
| US9663778B2 (en) * | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| HK1202434A1 (en) | 2011-11-22 | 2015-10-02 | The Children's Hospital Of Philadelphia | Virus vectors for highly efficient transgene delivery |
| CA3018046A1 (en) * | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| MX367100B (es) | 2012-02-17 | 2019-08-05 | The Children´S Hospital Of Philadelphia | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. |
| WO2014063753A1 (en) | 2012-10-26 | 2014-05-01 | Vrije Universiteit Brussel | Hyper-active factor ix vectors for liver-directed gene therapy of hemophilia 'b' and methods and use thereof |
| AU2013336601B2 (en) * | 2012-10-26 | 2018-01-25 | Vrije Universiteit Brussel | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
| US11007280B2 (en) | 2015-03-17 | 2021-05-18 | Vrije Universiteit Brussel | Optimized liver-specific expression systems for FVIII and FIX |
| MX390848B (es) * | 2015-06-23 | 2025-03-21 | Childrens Hospital Philadelphia | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. |
| CN106497949A (zh) * | 2016-10-14 | 2017-03-15 | 上海交通大学医学院附属瑞金医院 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
-
2018
- 2018-05-22 CN CN201880042428.9A patent/CN110945127B/zh active Active
- 2018-05-22 MX MX2019013836A patent/MX2019013836A/es unknown
- 2018-05-22 KR KR1020197037828A patent/KR102386890B1/ko active Active
- 2018-05-22 WO PCT/US2018/033866 patent/WO2018217731A1/en not_active Ceased
- 2018-05-22 NZ NZ759034A patent/NZ759034A/en unknown
- 2018-05-22 CN CN202410819836.8A patent/CN118581121A/zh active Pending
- 2018-05-22 AR ARP180101356A patent/AR112057A1/es unknown
- 2018-05-22 BR BR112019024256A patent/BR112019024256A2/pt not_active Application Discontinuation
- 2018-05-22 AU AU2018272831A patent/AU2018272831B2/en active Active
- 2018-05-22 KR KR1020227012028A patent/KR102551733B1/ko active Active
- 2018-05-22 IL IL280637A patent/IL280637B2/en unknown
- 2018-05-22 CA CA3064730A patent/CA3064730A1/en active Pending
- 2018-05-22 TW TW107117388A patent/TWI753168B/zh active
- 2018-05-22 EP EP18731636.9A patent/EP3630974A1/en not_active Withdrawn
- 2018-05-22 US US15/986,350 patent/US10842853B2/en active Active
- 2018-05-22 JP JP2019564430A patent/JP6961171B2/ja active Active
-
2019
- 2019-11-11 IL IL270567A patent/IL270567B/en active IP Right Grant
- 2019-11-18 CO CONC2019/0012885A patent/CO2019012885A2/es unknown
- 2019-11-20 MX MX2024009571A patent/MX2024009571A/es unknown
- 2019-11-21 ZA ZA2019/07716A patent/ZA201907716B/en unknown
- 2019-11-21 CL CL2019003395A patent/CL2019003395A1/es unknown
-
2020
- 2020-09-23 CL CL2020002445A patent/CL2020002445A1/es unknown
- 2020-10-20 US US17/075,556 patent/US20210128700A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2438931B1 (en) * | 2004-09-22 | 2013-11-13 | St. Jude Children's Research Hospital | Improved expression of factor IX in gene therapy vectors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI753168B (zh) | 用於血友病ｂ基因療法之編碼具有增強表現的重組ｆｉｘ變異體之病毒載體 | |
| TWI777175B (zh) | 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體 | |
| US20240100128A1 (en) | Gene therapy of hemophilia b using viral vectors encoding recombinant fix variants with increased expression | |
| TWI851647B (zh) | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 | |
| TWI823830B (zh) | 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體 | |
| US20250043310A1 (en) | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression | |
| CN111108196A (zh) | 凝血因子变体及其用途 | |
| US20230023826A1 (en) | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression | |
| RU2773956C2 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fix с повышенной экспрессией, для генотерапии гемофилии в | |
| EA047630B1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии а |